CLIA certified subtyping services for patients, clinicians, and drug developers.
Autologous and allogeneic
T-cell therapies for cancer.
For initial indications of SIRS/severe sepsis and myocardial infarction.
Improving survival and cardiac function post MI.
Please contact us if you would like to discuss this Program.